GNMLF Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of 9.77% compared to Genomma Lab Internacional SAB de CV's net margin of -116.82%. Genomma Lab Internacional SAB de CV's return on equity of 15.81% beat Agenus, Inc.'s return on equity of --.

Genomma Lab Internacional SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 267.06%. Given that Agenus, Inc. has higher upside potential than Genomma Lab Internacional SAB de CV, analysts believe Agenus, Inc. is more attractive than Genomma Lab Internacional SAB de CV.

Genomma Lab Internacional SAB de CV has a beta of 0.154, which suggesting that the stock is 84.555% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.

Genomma Lab Internacional SAB de CV has a quarterly dividend of $0.01 per share corresponding to a yield of 4.26%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genomma Lab Internacional SAB de CV pays 52.14% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend. Genomma Lab Internacional SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genomma Lab Internacional SAB de CV quarterly revenues are $238.4M, which are larger than Agenus, Inc. quarterly revenues of $30.2M. Genomma Lab Internacional SAB de CV's net income of $23.3M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Genomma Lab Internacional SAB de CV's price-to-earnings ratio is 10.92x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genomma Lab Internacional SAB de CV is 1.05x versus 0.85x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of 9.77% compared to Genomma Lab Internacional SAB de CV's net margin of 16.99%. Genomma Lab Internacional SAB de CV's return on equity of 15.81% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Genomma Lab Internacional SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.97%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Genomma Lab Internacional SAB de CV, analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Genomma Lab Internacional SAB de CV.

Genomma Lab Internacional SAB de CV has a beta of 0.154, which suggesting that the stock is 84.555% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Genomma Lab Internacional SAB de CV has a quarterly dividend of $0.01 per share corresponding to a yield of 4.26%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genomma Lab Internacional SAB de CV pays 52.14% of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Genomma Lab Internacional SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genomma Lab Internacional SAB de CV quarterly revenues are $238.4M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Genomma Lab Internacional SAB de CV's net income of $23.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Genomma Lab Internacional SAB de CV's price-to-earnings ratio is 10.92x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 146.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genomma Lab Internacional SAB de CV is 1.05x versus 11.91x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Corporativo Fragua SAB de CV has a net margin of 9.77% compared to Genomma Lab Internacional SAB de CV's net margin of --. Genomma Lab Internacional SAB de CV's return on equity of 15.81% beat Corporativo Fragua SAB de CV's return on equity of --.

Genomma Lab Internacional SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand Corporativo Fragua SAB de CV has an analysts' consensus of -- which suggests that it could fall by --. Given that Genomma Lab Internacional SAB de CV has higher upside potential than Corporativo Fragua SAB de CV, analysts believe Genomma Lab Internacional SAB de CV is more attractive than Corporativo Fragua SAB de CV.

Genomma Lab Internacional SAB de CV has a beta of 0.154, which suggesting that the stock is 84.555% less volatile than S&P 500. In comparison Corporativo Fragua SAB de CV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genomma Lab Internacional SAB de CV has a quarterly dividend of $0.01 per share corresponding to a yield of 4.26%. Corporativo Fragua SAB de CV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genomma Lab Internacional SAB de CV pays 52.14% of its earnings as a dividend. Corporativo Fragua SAB de CV pays out -- of its earnings as a dividend. Genomma Lab Internacional SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genomma Lab Internacional SAB de CV quarterly revenues are $238.4M, which are larger than Corporativo Fragua SAB de CV quarterly revenues of --. Genomma Lab Internacional SAB de CV's net income of $23.3M is higher than Corporativo Fragua SAB de CV's net income of --. Notably, Genomma Lab Internacional SAB de CV's price-to-earnings ratio is 10.92x while Corporativo Fragua SAB de CV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genomma Lab Internacional SAB de CV is 1.05x versus -- for Corporativo Fragua SAB de CV. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of 9.77% compared to Genomma Lab Internacional SAB de CV's net margin of --. Genomma Lab Internacional SAB de CV's return on equity of 15.81% beat Savara, Inc.'s return on equity of -78.83%.

Genomma Lab Internacional SAB de CV has a consensus price target of --, signalling downside risk potential of --. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 81.11%. Given that Savara, Inc. has higher upside potential than Genomma Lab Internacional SAB de CV, analysts believe Savara, Inc. is more attractive than Genomma Lab Internacional SAB de CV.

Genomma Lab Internacional SAB de CV has a beta of 0.154, which suggesting that the stock is 84.555% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Genomma Lab Internacional SAB de CV has a quarterly dividend of $0.01 per share corresponding to a yield of 4.26%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genomma Lab Internacional SAB de CV pays 52.14% of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend. Genomma Lab Internacional SAB de CV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genomma Lab Internacional SAB de CV quarterly revenues are $238.4M, which are larger than Savara, Inc. quarterly revenues of --. Genomma Lab Internacional SAB de CV's net income of $23.3M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Genomma Lab Internacional SAB de CV's price-to-earnings ratio is 10.92x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genomma Lab Internacional SAB de CV is 1.05x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.